CGEM
NASDAQCullinan Therapeutics Inc.
Price$12.90-0.78 (-5.70%)
01:30 PM07:45 PM
News · 26 weeks49+50%
2026-04-192026-10-11
Mix2090d
- Other11(55%)
- SEC Filings6(30%)
- Insider2(10%)
- Earnings1(5%)
Latest news
25 items- PRCullinan Therapeutics Announces First Patient Dosed in Planned Registrational Phase 2 Study of CLN-049 in Relapsed/Refractory Acute Myeloid LeukemiaCAMBRIDGE, Mass., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM, "Cullinan")), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced that the first patient has been dosed in its pivotal Phase 2 study of CLN-049, a novel, investigational FLT3 T cell engager, in patients with relapsed/refractory acute myeloid leukemia (AML). "Patients with relapsed or refractory AML continue to face poor outcomes and limited treatment options, underscoring the urgent need for new treatment approaches that can benefit a broad range of patients," said Jeffrey J
- SECCullinan Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Cullinan Therapeutics, Inc. (0001789972) (Filer)
- PRNew Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review ProgramIn the Phase 3 REZILIENT3 study, zipalertinib combination therapy demonstrated longest median progression-free survival observed to date in first-line EGFR exon20ins NSCLC After agreement with the U.S. FDA, Real-Time Oncology Review program submission process initiated; completion of NDA submission expected by year-end 2026 CAMBRIDGE, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced the initiation of a New Drug Application (NDA) submission to the U.S. Food and Drug Administration
- SECCullinan Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Cullinan Therapeutics, Inc. (0001789972) (Filer)
- PRCullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager PortfolioVelinotamig (BCMA TCE) multi-dose regimen data in SLE at ACR Convergence 2026 in November CLN-978 (CD19 TCE) multi-dose regimen data in SLE, RA and Sjögren’s disease in December CLN-049 (FLT3 TCE) updated data from the Phase 1 dose escalation study in December CAMBRIDGE, Mass., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM, "Cullinan")), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today outlined fourth quarter 2026 milestones across its immunology and oncology pipeline. "We look forward to providing several updates across our T cell engager
- PRCullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation ForumCAMBRIDGE, Mass., Sept. 21, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM, "Cullinan")), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced that Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Stifel 2026 Virtual Immunology and Inflammation Forum on Thursday, September 24, 2026, at 1:30 p.m. ET. A webcast of the fireside chat will be available under the Events and Presentations section of the Company’s investor relations website at https://investors.cullinant
- SECCullinan Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Cullinan Therapeutics, Inc. (0001789972) (Filer)
- PRCullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung CancerCAMBRIDGE, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced that it will host a virtual event for analysts and institutional investors today at 8:00 a.m. ET to discuss the results from the planned interim analysis of the Phase 3 REZILIENT3 trial of zipalertinib plus chemotherapy presented in Presidential Symposium 2 at the International Association for the Study of Lung Cancer’s (IASLC) 2026 World Conference on Lung Cancer (WCLC). Virtual Event Details Cullinan Therapeutics w
- PRCullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung CancerResults from the planned interim analysis of the Phase 3 REZILIENT3 trial of zipalertinib plus chemotherapy in first-line EGFR exon 20 insertion mutation NSCLC to be presented in Presidential Symposium 2 on Sunday, September 13, 2026 Company to host a virtual event on Monday, September 14, 2026, at 8:00 a.m. ET CAMBRIDGE, Mass., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced that it will host a virtual event for analysts and institutional investors on Monday, September 14, 2026, at 8:
- INSIDERChief Scientific Officer Michaelson Jennifer sold $172,560 worth of shares (8,000 units at $21.57) as part of a pre-agreed trading plan and exercised 4,000 shares at a strike of $4.30, decreasing direct ownership by 2% to 158,844 units (SEC Form 4)4 - Cullinan Therapeutics, Inc. (0001789972) (Issuer)
- PRZipalertinib Plus Chemotherapy First-Line Phase 3 REZILIENT3 Trial Data Selected for Presidential Symposium Presentation at the IASLC 2026 World Conference on Lung CancerPresentation will feature results from the planned interim analysis of the Phase 3 REZILIENT3 trial, which met its primary endpoint of progression-free survival in first line EGFR exon 20 insertion mutation NSCLC Taiho Oncology, Inc. and Cullinan Therapeutics, Inc. (NASDAQ:CGEM) today announced that results from the planned interim analysis of the Phase 3 REZILIENT3 trial have been selected for presentation in the Presidential Symposium 2 at the International Association for the Study of Lung Cancer's (IASLC) 2026 World Conference on Lung Cancer (WCLC), to be held September 12-15, 2026, in Seoul, South Korea. REZILIENT3 evaluates zipalertinib plus chemotherapy versus chemotherapy alone in
- INSIDERChief Scientific Officer Michaelson Jennifer exercised 30,000 shares at a strike of $4.30 and sold $607,800 worth of shares (30,000 units at $20.26) as part of a pre-agreed trading plan (SEC Form 4)4 - Cullinan Therapeutics, Inc. (0001789972) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Cullinan Therapeutics Inc.SCHEDULE 13G - Cullinan Therapeutics, Inc. (0001789972) (Subject)
- SECCullinan Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Cullinan Therapeutics, Inc. (0001789972) (Filer)
- PRZipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung CancerTaiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (NASDAQ:CGEM) today announced that the REZILIENT3 trial, a global Phase 3 clinical trial evaluating the combination of zipalertinib and platinum-based chemotherapy compared with chemotherapy alone in the first-line treatment of adult patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations, met its primary endpoint of progression-free survival (PFS) at a planned interim analysis. In this analysis, the study demonstrated a statistically significant and clinically meaningful
- SECSEC Form SCHEDULE 13G filed by Cullinan Therapeutics Inc.SCHEDULE 13G - Cullinan Therapeutics, Inc. (0001789972) (Subject)
- SECSEC Form 10-Q filed by Cullinan Therapeutics Inc.10-Q - Cullinan Therapeutics, Inc. (0001789972) (Filer)
- SECCullinan Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Cullinan Therapeutics, Inc. (0001789972) (Filer)
- PRCullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial ResultsCLN-978 (CD19 TCE) multi-dose regimen data in RA in Q3 2026 and SLE in Q4 2026; Phase 2 expansion studies to begin early 2027 Velinotamig (BCMA TCE) multi-dose regimen data in SLE in Q4 2026; Phase 1/2 basket study in autoimmune cytopenias to begin early 2027 CLN-049 (FLT3 TCE) potentially registrational Phase 2 study in R/R AML to begin in Q3 2026 Cash and investments of $356 million as of June 30, 2026; runway into 2029 CAMBRIDGE, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM, "Cullinan")), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer,
- PRCullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AMLCAMBRIDGE, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM, "Cullinan")), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced positive feedback from the U.S. Food and Drug Administration (FDA) following an End-of-Phase 1 (EOP1) meeting for CLN-049, a FLT3xCD3 T cell engager being evaluated in patients with acute myeloid leukemia (AML). The EOP1 meeting focused on the planned Phase 2 development strategy for CLN-049. Based on discussions with the FDA, Cullinan will initiate a potentially registrational Phase 2 study of CLN-049 in pati
- INSIDERChief Scientific Officer Michaelson Jennifer exercised 4,000 shares at a strike of $4.30 and sold $142,560 worth of shares (8,000 units at $17.82) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 162,844 units (SEC Form 4)4 - Cullinan Therapeutics, Inc. (0001789972) (Issuer)
- INSIDERChief Legal Officer Sumer Jacquelyn L was granted 2,470 shares, increasing direct ownership by 2% to 130,559 units (SEC Form 4)4 - Cullinan Therapeutics, Inc. (0001789972) (Issuer)
- INSIDERChief Financial Officer Fenton Mary Kay was granted 1,541 shares, increasing direct ownership by 1% to 127,921 units (SEC Form 4)4 - Cullinan Therapeutics, Inc. (0001789972) (Issuer)
- INSIDERSEC Form 4 filed by Director Rosenberg Anthony4 - Cullinan Therapeutics, Inc. (0001789972) (Issuer)
- INSIDERSEC Form 4 filed by Director Allen Andrew R4 - Cullinan Therapeutics, Inc. (0001789972) (Issuer)
CGEM FAQ
7 questionsWhat does Cullinan Therapeutics Inc. do?
Cullinan Management, Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the...Where does CGEM stock trade?
Cullinan Therapeutics Inc. (CGEM) is listed on NASDAQ.What sector and industry is CGEM in?
Cullinan Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Cullinan Therapeutics Inc. go public?
Cullinan Therapeutics Inc. (CGEM) completed its IPO in 2021.What are analysts saying about CGEM?
Cullinan Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Citigroup: Buy with a $3300.00 price target on 2026-02-17. Recent price targets range from $2200.00 to $4000.00.What companies are similar to CGEM?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare CGEM side-by-side with any of them on Quantisnow.How can I track CGEM on Quantisnow?
Quantisnow aggregates Cullinan Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CGEM to receive live email and push alerts on every new disclosure.